PHARMACEUTICAL COMPOSITION OF NAPHTHALENE DERIVATIVES AS MULTI-TARGETED THERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

• Main Authors: BENCOMO MARTÍNEZ, Alberto, CERVANTES LLANOS, Majel, PÉREZ PERERA, Rafaela, SABLÓN CARRAZANA, Marquiza, ÁGUILA CORDOVA, Adriana, CASTRO-PALOMINO ANTELA, Kathleen, OTAÑO TAMAYO, Laura, LEÓN CHAVIANO, Samila, MENÉNDEZ SOTO DEL VALLE, Roberto, RIVERA MARRERO, Suchitil, DÍAZ GARCÍA, Orestes de Jesús, GARCÍA PUPO, Laura, GONZÁLEZ MESA, Leonora, PENTÓN ROL, Giselle, RODRÍGUEZ-TANTY, Chryslaine, DORESTE BROWN, Miriam
• Format: Patent
• Language: English
• Published: 12.09.2024
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

This invention relates to pharmaceutical chemistry and specifically to the pharmaceutical composition of the compounds, which show multi-targeted action on the cholinergic, glutamatergic and mitochondrial systems that are affected in Alzheimer's Disease (AD), whose general Formula (I) is I, wherein the substituents R1 and R2 are set out in the description and claims. The formulation of these compounds increases effectiveness and tolerance in oral, sublingual, parenteral, transdermal and nasal administration. They can be used on their own, as monotherapy, as a replacement of the multi-therapy currently used for AD. The formulation of these compounds, their salts, hydrates, enantiomers, isomers, metabolites, prodrugs for administration to humans, as active ingredients for the treatment of AD, increases bioavailability, residence time of the active ingredient and adequate excretion, which increases the effectiveness, biosafety, adherence and tolerance to the treatment.